Yoda Pharmaceuticals Inc. (TPEX:7829)

Market Cap	3.59B
Revenue (ttm)	n/a
Net Income	-315.73M
EPS	-4.35
Shares Out	79.39M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	161,783
Average Volume	189,699
Open	46.90
Previous Close	47.35
Day's Range	45.05 - 47.00
52-Week Range	32.65 - 77.60
Beta	n/a
RSI	25.94
Earnings Date	Apr 29, 2026

About Yoda Pharmaceuticals

Yoda Pharmaceuticals Inc., an AI-driven company, focuses on development of drugs targeting central nervous system disorders. The company’s flagship drug, YA-101 is in Phase 2 clinical trial for the treatment of multiple system atrophy. It is also involved in the development pipeline includes drugs in the field of neurological and psychiatric disorders and cerebrovascular diseases, targeting conditions, such as schizophrenia, Alzheimer's disease, Parkinson‘s disease, Autism, ischemic stroke, and traumatic brain injury. Yoda Pharmaceuticals Inc. ...

• Industry: Pharmaceutical Preparations
• Founded: 2019
• Country: Cayman Islands
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7829